If You Invested in Senzime Ab (SNZZF)
Looking for the live price? See the SNZZF quote & overviewWhat $1,000 or $10,000 in SNZZF Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Feb 1, 2017 |
|---|---|---|---|---|
| $1,000 | $833 -17% | $175 -83% | — | $648 -35% |
| $10,000 | $8,326 -17% | $1,749 -83% | — | $6,477 -35% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for SNZZF$1,000 Investment Over Time
SNZZF vs S&P 500Year-by-Year Returns
SNZZF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $0.73 | $0.81 | +10.4% | +10.4% |
| 2018 | $0.81 | $0.76 | -5.9% | +3.9% |
| 2019 | $0.76 | $1.55 | +103.8% | +111.9% |
| 2020 | $1.55 | $2.55 | +64.4% | +248.2% |
| 2021 | $2.55 | $2.33 | -8.6% | +218.3% |
| 2022 | $2.33 | $0.95 | -59.2% | +29.9% |
| 2023 | $0.95 | $0.77 | -18.9% | +5.3% |
| 2024 | $0.79 | $0.53 | -33.3% | -27.9% |
| 2025 | $0.53 | $0.54 | +2.8% | -25.9% |
| 2026 | $0.62 | $0.47 | -23.3% | -35.2% |
About Senzime Ab
Healthcare · OTC Link
Senzime AB (SNZZF) develops and markets medical device systems for precision monitoring in anesthesia and perioperative care. The company’s flagship TetraGraph system monitors neuromuscular transmission during surgery, a clinical function used to guide dosing of neuromuscular blocking drugs and support recovery from anesthesia. Senzime is headquartered in Uppsala, Sweden, was established in 1999, is listed on the Nasdaq Stockholm Main Market under SEZI, and its ordinary shares cross-trade on the OTCQX Market as SNZZF.
The company’s product focus is centered on perioperative patient safety and operating-room monitoring. TetraGraph is used by anesthesia teams to generate objective neuromuscular data during surgical care. The system is marketed to hospitals and health systems, including integrated delivery networks in the United States, where centralized purchasing decisions can support system-wide adoption across affiliated facilities.
Senzime also offers TetraCom, a hospital connectivity platform designed to transmit real-time neuromuscular data from TetraGraph into electronic health record and clinical information systems. TetraCom combines a compact hardware gateway with a cloud-based software component and uses HL7 messaging to support interoperability with hospital enterprise systems such as Epic and Oracle Health systems. This extends the company’s role from device-based monitoring into anesthesia data integration for hospital information environments.
The company’s commercial model includes sales of monitoring systems to hospitals and healthcare networks, along with recurring revenue associated with installed systems. In the United States, Senzime’s commercial activity includes hospital contracts, integrated delivery network expansion, and access through group purchasing organization agreements. Its operating structure also includes sales, clinical, and medical-affairs functions that support hospital adoption, training, and use of the company’s monitoring technology.
Senzime operates within the medical device market for perioperative and anesthesia care. Its business is shaped by hospital procurement processes, operating-room clinical practice, and the broader shift toward quantitative monitoring and digital transmission of clinical data during surgery and recovery.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Senzime Ab investment returns
How much would $1,000 invested in Senzime Ab be worth today?
If you invested $1,000 in Senzime Ab (SNZZF) 5 years ago on 2021-07-07, your investment would be worth $175 today, representing a -82.5% total return, growing at a compounded rate of -29.5% per year (CAGR).
Has Senzime Ab outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare SNZZF performance over available time periods.
What is Senzime Ab's average annual return?
The compound annual growth rate (CAGR) of SNZZF over the past 5 years is -29.5%, growing at a compounded rate each year. Individual years vary significantly — SNZZF's best recent year was 2019 (+103.8%) and worst was 2022 (-59.2%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
